Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDER Organizational Development Team To Be Headed By EPA’s Wright

Executive Summary

CDER's Organizational Development & Strategic Planning Team will be headed by Kenneth Wright, who led several organizational changes during his 25-year tenure at the Environmental Protection Agency

You may also be interested in...

FDA Oncology Reviews Could Remain Split After CBER/CDER Reorganization

FDA is understood to be considering the creation of two divisions within the Center for Drug Evaluation & Research to review oncologic products as part of the CBER/CDER reorganization

FDA Commissioner’s Office To Be Re-aligned Further Under Booz Allen Plan

FDA's Office of the Commissioner will be re-aligned further by the end of fiscal year 2003 with the assistance of Booz Allen Hamilton consultants

CDER Deputy Galson Brings Risk Management Experience To FDA Surveillance

FDA Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, has experience in public health risk assessment that will contribute to the center's revamping of its postmarketing surveillance program.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts